GlassScriptPhysician profile
Rashid Iqbal
NPI 1942285879
$647.32
in general payments reported to CMS, 2019-2025
9 companies · $288 in 2025
The $288 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.45 · 2022: $42.86 · 2023: $161 · 2024: $124 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.61 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $199.10 | 2023-2025 | Tremfya, Remicade, Stelara |
| Pfizer INC. | $108.94 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.09 | 2023-2025 | Entyvio, Eohilia |
| Abbvie INC. | $103.63 | 2021-2025 | |
| Celgene Corporation | $42.29 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $34.83 | 2023 | Dupixent |
| Capsovision, INC. | $23.77 | 2024 | Capsocam Plus |
| Boston Scientific Corporation | $16.82 | 2022 | |
| Intercept Pharmaceuticals, INC. | $13.85 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashid Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.